<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03529942</url>
  </required_header>
  <id_info>
    <org_study_id>FX006-2017-014</org_study_id>
    <nct_id>NCT03529942</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effect of FX006 on Synovial Inflammation in Patients With OA of the Knee</brief_title>
  <official_title>An Open-Label Study to Evaluate the Effect of the Administration of FX006 on Synovial Inflammation in Patients With Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Flexion Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Flexion Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label study assessing the effect of the administration of a single&#xD;
      intra-articular (IA) injection of FX006 32 mg on synovial volume in patients with&#xD;
      osteoarthritis (OA) of the knee.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label study assessing the effect of the administration of a single&#xD;
      intra-articular (IA) injection of FX006 32 mg on synovial volume in patients with&#xD;
      osteoarthritis (OA) of the knee. The study will be conducted in male and female patients who&#xD;
      are ≥ 40 years of age.&#xD;
&#xD;
      Eligible patients who provide written consent and meet all entry criteria will undergo&#xD;
      initial ultrasound examination and MRI with contrast of the index knee, and then receive a&#xD;
      single IA injection of FX006 administered to the index knee at Baseline/Day 1. Patients will&#xD;
      return to the clinic at Weeks 6 and 24 for an MRI with contrast of the index knee and other&#xD;
      assessments. Patients must also have a blood sample drawn for Estimated Glomerular Filtration&#xD;
      Rate (eGFR) testing within 30 days prior to the scheduled MRIs. In addition, a patient&#xD;
      questionnaire will be administered and adverse events (AEs) and concomitant medication&#xD;
      updates will be collected via telephone at Weeks 12 and 18.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 24, 2018</start_date>
  <completion_date type="Actual">March 9, 2020</completion_date>
  <primary_completion_date type="Actual">November 8, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Standardized Change in Synovial Volume (SV) at 6 Weeks</measure>
    <time_frame>Baseline to Week 6</time_frame>
    <description>Synovial volume (mm^3) as measured by MRI and read by a central imaging vendor. Standardization was performed by dividing the model-derived least squares means and corresponding confidence intervals by the adjusted standard deviation (SD). Therefore, the mean standardized change represents the change in synovial volume expressed in standard deviation units.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Change in Synovial Volume at 6 Weeks</measure>
    <time_frame>Baseline to Week 6</time_frame>
    <description>Mean absolute change from baseline at 6 weeks in synovial volume (mm^3) as measured by MRI and read by a central imaging vendor. The least squares mean changes are estimated using a mixed effects model for repeated measures with fixed effects for study time point, study site, baseline score and baseline femur bone volume (mm^3) and a random effect for patient.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Standardized Change in Synovial Volume (SV) at 24 Weeks</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Synovial volume (mm^3) as measured by MRI and read by a central imaging vendor. Standardization was performed by dividing the model-derived least squares means and corresponding confidence intervals by the adjusted standard deviation (SD). Therefore, the mean standardized change represents the change in synovial volume expressed in standard deviation units.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Absolute Change in Synovial Volume at 24 Weeks</measure>
    <time_frame>Baseline to Week 24</time_frame>
    <description>Mean absolute change (mm^3) from baseline at 24 weeks in synovial volume (mm^3) as measured by MRI and read by a central imaging vendor. The least squares mean changes are estimated using a mixed effects model for repeated measures with fixed effects for study time point, study site, baseline score and baseline femur bone volume (mm^3) and a random effect for patient.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">129</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>FX006 32 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single intra-articular (IA) injection of FX006 32 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FX006 32 mg</intervention_name>
    <description>Extended-release 32 mg FX006 IA injection</description>
    <arm_group_label>FX006 32 mg</arm_group_label>
    <other_name>Zilretta</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written consent to participate in the study&#xD;
&#xD;
          -  Male or female ≥ 40 years of age&#xD;
&#xD;
          -  Body mass index (BMI) ≤ 40 kg/m^2&#xD;
&#xD;
          -  Ambulatory and in good general health&#xD;
&#xD;
          -  Willing and able to comply with the study procedures and visit schedules and able to&#xD;
             follow verbal and written instructions&#xD;
&#xD;
          -  Willing to abstain from use of protocol-restricted medications during the study&#xD;
&#xD;
          -  Symptoms associated with OA of the index knee for ≥ 6 months prior to Screening&#xD;
             (patient self-report is acceptable)&#xD;
&#xD;
          -  Currently meets American College of Rheumatology (ACR) Criteria (clinical and&#xD;
             radiological) for OA&#xD;
&#xD;
          -  Kellgren-Lawrence (K-L) Grade 2 or 3 in the index knee based on X-ray performed during&#xD;
             Screening (centrally read)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any inflammatory arthritis including reactive arthritis, rheumatoid arthritis,&#xD;
             psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory&#xD;
             bowel disease, gout or secondary OA from gout&#xD;
&#xD;
          -  History of infection or crystal disease in the index knee joint&#xD;
&#xD;
          -  Unstable index knee joint (such as a torn anterior cruciate ligament) within 12 months&#xD;
             of Screening&#xD;
&#xD;
          -  Surgery or arthroscopy of the index knee within 12 months of Screening&#xD;
&#xD;
          -  IA corticosteroid (investigational or marketed) in any joint within 3 months of&#xD;
             Screening&#xD;
&#xD;
          -  IA treatment of the index knee with hyaluronic acid (investigational or marketed)&#xD;
             within 6 months of Screening&#xD;
&#xD;
          -  IV or IM corticosteroids (investigational or marketed) within 3 months of Screening&#xD;
&#xD;
          -  Oral corticosteroids (investigational or marketed) within 1 month of Screening&#xD;
&#xD;
          -  Any other IA drug/biologic in the index knee within 6 months of Screening or 5&#xD;
             half-lives (whichever is longer) (e.g., platelet rich plasma (PRP) injection, stem&#xD;
             cells, prolotherapy and amniotic fluid injection)&#xD;
&#xD;
          -  Prior administration of FX006&#xD;
&#xD;
          -  eGFR results &lt;40 mL/minute&#xD;
&#xD;
          -  Any contraindication to MRI Scanning (e.g., presence of certain ferromagnetic foreign&#xD;
             bodies or electronic devices including most cardiac pacemakers, claustrophobia)&#xD;
&#xD;
          -  Known hypersensitivity to any form of radiographic contrast&#xD;
&#xD;
          -  Females who are pregnant or nursing or plan to become pregnant during the study; men&#xD;
             who plan to conceive during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Scott Kelley, MD</last_name>
    <role>Study Director</role>
    <affiliation>Flexion Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>TriWest Research Associates, LLC</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Biosolutions Research</name>
      <address>
        <city>La Mesa</city>
        <state>California</state>
        <zip>91942</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dream Team Clinical Research (formerly located in Anaheim)</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dream Team Clinical Research</name>
      <address>
        <city>Pomona</city>
        <state>California</state>
        <zip>91767</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tampa Bay Medical Research, Inc.</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rush University Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center for Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PMG Research, Inc. d/b/a PMG Research of Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37938</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Leeds</name>
      <address>
        <city>Leeds</city>
        <zip>LS7 4SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>May 8, 2018</study_first_submitted>
  <study_first_submitted_qc>May 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2018</study_first_posted>
  <results_first_submitted>November 6, 2020</results_first_submitted>
  <results_first_submitted_qc>December 4, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 8, 2020</results_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Osteoarthritis</keyword>
  <keyword>Knee</keyword>
  <keyword>Pain</keyword>
  <keyword>Intra-articular</keyword>
  <keyword>Injection</keyword>
  <keyword>Corticosteroid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>FX006</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 12, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT03529942/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>May 9, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT03529942/ICF_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>November 5, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/42/NCT03529942/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>FX006 32mg</title>
          <description>All patients who received any amount of FX006 32mg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Reached Week 6 With Paired MRI</title>
              <participants_list>
                <participants group_id="P1" count="108"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="106"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Needle inserted but no drug administered</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All patients who received any amount of FX006 32mg</population>
      <group_list>
        <group group_id="B1">
          <title>Total Population</title>
          <description>All patients who received any amount of FX006 32mg</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="129"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="81"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="108"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Standardized Change in Synovial Volume (SV) at 6 Weeks</title>
        <description>Synovial volume (mm^3) as measured by MRI and read by a central imaging vendor. Standardization was performed by dividing the model-derived least squares means and corresponding confidence intervals by the adjusted standard deviation (SD). Therefore, the mean standardized change represents the change in synovial volume expressed in standard deviation units.</description>
        <time_frame>Baseline to Week 6</time_frame>
        <population>Participants with pre-treatment synovial volume measurement as determined by quantitative image analysis, as well as a quality Week 6 MRI who received a single intra-articular (IA) injection of FX006 32 mg</population>
        <group_list>
          <group group_id="O1">
            <title>Total Population</title>
            <description>All patients who received a single intra-articular (IA) injection of FX006 32mg and had a pre-treatment synovial volume measurement</description>
          </group>
          <group group_id="O2">
            <title>Patients With Baseline Synovitis</title>
            <description>The subset of the Total Population who had a pre-treatment synovial volume measurement of greater than 3000 mm^3 of gadolinium enhancement as determined by quantitative image analysis</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Standardized Change in Synovial Volume (SV) at 6 Weeks</title>
          <description>Synovial volume (mm^3) as measured by MRI and read by a central imaging vendor. Standardization was performed by dividing the model-derived least squares means and corresponding confidence intervals by the adjusted standard deviation (SD). Therefore, the mean standardized change represents the change in synovial volume expressed in standard deviation units.</description>
          <population>Participants with pre-treatment synovial volume measurement as determined by quantitative image analysis, as well as a quality Week 6 MRI who received a single intra-articular (IA) injection of FX006 32 mg</population>
          <units>Standardized Units</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.67" lower_limit="-0.8131" upper_limit="-0.5296"/>
                    <measurement group_id="O2" value="-0.9" lower_limit="-1.0573" upper_limit="-0.7341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Absolute Change in Synovial Volume at 6 Weeks</title>
        <description>Mean absolute change from baseline at 6 weeks in synovial volume (mm^3) as measured by MRI and read by a central imaging vendor. The least squares mean changes are estimated using a mixed effects model for repeated measures with fixed effects for study time point, study site, baseline score and baseline femur bone volume (mm^3) and a random effect for patient.</description>
        <time_frame>Baseline to Week 6</time_frame>
        <population>Participants with pre treatment synovial volume measurement as determined by quantitative image analysis, as well as a quality Week 6 MRI who received a single intra-articular (IA) injection of FX006 32 mg</population>
        <group_list>
          <group group_id="O1">
            <title>Total Population</title>
            <description>All patients who received a single intra-articular (IA) injection of FX006 32mg and had a pre-treatment synovial volume measurement</description>
          </group>
          <group group_id="O2">
            <title>Patients With Baseline Synovitis</title>
            <description>The subset of the Total Population who had a pre-treatment synovial volume measurement of greater than 3000 mm^3 of gadolinium enhancement as determined by quantitative image analysis</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Change in Synovial Volume at 6 Weeks</title>
          <description>Mean absolute change from baseline at 6 weeks in synovial volume (mm^3) as measured by MRI and read by a central imaging vendor. The least squares mean changes are estimated using a mixed effects model for repeated measures with fixed effects for study time point, study site, baseline score and baseline femur bone volume (mm^3) and a random effect for patient.</description>
          <population>Participants with pre treatment synovial volume measurement as determined by quantitative image analysis, as well as a quality Week 6 MRI who received a single intra-articular (IA) injection of FX006 32 mg</population>
          <units>mm^3</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="84"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5469.68" spread="581.9123"/>
                    <measurement group_id="O2" value="-7549.55" spread="683.6488"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Standardized Change in Synovial Volume (SV) at 24 Weeks</title>
        <description>Synovial volume (mm^3) as measured by MRI and read by a central imaging vendor. Standardization was performed by dividing the model-derived least squares means and corresponding confidence intervals by the adjusted standard deviation (SD). Therefore, the mean standardized change represents the change in synovial volume expressed in standard deviation units.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Participants with pre treatment synovial volume measurement as determined by quantitative image analysis, as well as a quality Week 24 MRI who received a single intra-articular (IA) injection of FX006 32 mg</population>
        <group_list>
          <group group_id="O1">
            <title>Total Population</title>
            <description>All patients who received a single intra-articular (IA) injection of FX006 32 mg and had a pre-treatment synovial volume measurement</description>
          </group>
          <group group_id="O2">
            <title>Patients With Baseline Synovitis</title>
            <description>The subset of the Total Population who had a pre-treatment synovial volume measurement of greater than 3000 mm^3 of gadolinium enhancement as determined by quantitative image analysis</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Standardized Change in Synovial Volume (SV) at 24 Weeks</title>
          <description>Synovial volume (mm^3) as measured by MRI and read by a central imaging vendor. Standardization was performed by dividing the model-derived least squares means and corresponding confidence intervals by the adjusted standard deviation (SD). Therefore, the mean standardized change represents the change in synovial volume expressed in standard deviation units.</description>
          <population>Participants with pre treatment synovial volume measurement as determined by quantitative image analysis, as well as a quality Week 24 MRI who received a single intra-articular (IA) injection of FX006 32 mg</population>
          <units>Standardized Units</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.20" lower_limit="0.0536" upper_limit="0.3371"/>
                    <measurement group_id="O2" value="0.20" lower_limit="0.0385" upper_limit="0.3618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Absolute Change in Synovial Volume at 24 Weeks</title>
        <description>Mean absolute change (mm^3) from baseline at 24 weeks in synovial volume (mm^3) as measured by MRI and read by a central imaging vendor. The least squares mean changes are estimated using a mixed effects model for repeated measures with fixed effects for study time point, study site, baseline score and baseline femur bone volume (mm^3) and a random effect for patient.</description>
        <time_frame>Baseline to Week 24</time_frame>
        <population>Participants with pre-treatment synovial volume measurement as determined by quantitative image analysis, as well as a quality Week 24 MRI who received a single intra-articular (IA) injection of FX006 32 mg.</population>
        <group_list>
          <group group_id="O1">
            <title>Total Population</title>
            <description>All patients who received a single intra-articular (IA) injection of FX006 32 mg and had a pre-treatment synovial volume measurement</description>
          </group>
          <group group_id="O2">
            <title>Patients With Baseline Synovitis</title>
            <description>The subset of the Total Population who had a pre-treatment synovial volume measurement of greater than 3000 mm^3 of gadolinium enhancement as determined by quantitative image analysis</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Change in Synovial Volume at 24 Weeks</title>
          <description>Mean absolute change (mm^3) from baseline at 24 weeks in synovial volume (mm^3) as measured by MRI and read by a central imaging vendor. The least squares mean changes are estimated using a mixed effects model for repeated measures with fixed effects for study time point, study site, baseline score and baseline femur bone volume (mm^3) and a random effect for patient.</description>
          <population>Participants with pre-treatment synovial volume measurement as determined by quantitative image analysis, as well as a quality Week 24 MRI who received a single intra-articular (IA) injection of FX006 32 mg.</population>
          <units>mm^3</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="88"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3239.94" spread="1184.5800"/>
                    <measurement group_id="O2" value="3476.52" spread="1408.7997"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through study completion; up to 28 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Total Population</title>
          <description>All patients who received an attempted single intra-articular (IA) injection of FX006 32 mg</description>
        </group>
        <group group_id="E2">
          <title>Patients With Baseline Synovitis</title>
          <description>The subset of the Total Population who had a pre-treatment synovial volume measurement of greater than 3000 mm^3 of gadolinium enhancement as determined by quantitative image analysis</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Lymph Node Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Thyroid Cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute Sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Otitis Media</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Joint Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Limb Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Meniscus Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Procedural Anxiety</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Synovial Rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Cardiac Murmur</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="129"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Joint Effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Joint Swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal Pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="102"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>One patient experienced procedural anxiety during the placement of the syringe on the inserted needle and did not receive the full dose of FX006. This patient is still counted in the safety population.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Scott Kelley, Chief Medical Officer</name_or_title>
      <organization>Flexion Therapeutics</organization>
      <phone>781-305-7142</phone>
      <email>skelley@flexiontherapeutics.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

